Chebulagic acid | COX Inhibitor | AmBeed-信号通路专用抑制剂

Chebulagic acid/诃子鞣酸 {[allProObj[0].p_purity_real_show]}

货号：A311069

Chebulagic acid是一种从 Terminalia chebula Retz 果实中分离的 COX-LOX 双重抑制剂，具有抑制血管生成的作用。

Chebulagic acid/诃子鞣酸化学结构
CAS号：23094-71-5

Chebulagic acid/诃子鞣酸 3D分子结构
CAS号：23094-71-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Chebulagic acid/诃子鞣酸纯度/质量文件产品仅供科研

货号：A311069 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

Chebulagic acid/诃子鞣酸质控信息

脂氧合酶亚型比较

环氧化酶亚型比较

产品名称	lipoxygenase ↓ ↑	纯度
Zileuton	✔	97%
Nordihydroguaiaretic acid	✔	99%+
MK-886	✔	99%+
Esculetin	✔	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	COX ↓ ↑	COX-1 ↓ ↑	COX-2 ↓ ↑	纯度
Piroxicam	✔			98%
Salicylic acid	✔			98%
Phenacetin	✔			98%
Etodolac	✔			99%
Flunixin meglumine	✔			98%
Ibuprofen L-lysine	✔			98%
Nabumetone	✔			98%
Acemetacin	✔			98%
Diflunisal	✔			98%
Pranoprofen	✔			98%
Ampiroxicam	✔			98%
Meloxicam	✔			98%
Sulindac	✔			98%
Ketoprofen		✔		98%
Mefenamic Acid		✔		95%
Bromfenac sodium		✔		98%
Oxaprozin		✔		99%
Aspirin		✔		99%
Nepafenac		✔		98%
Zaltoprofen		✔		99%
Salicin		✔		98%
Suprofen		✔		99%+
Xanthohumol		✔		99%
Parecoxib			✔	98%
Tolfenamic Acid			+++ COX-2, IC50: 0.2 μM	98%
Etoricoxib			✔	99%
Niflumic Acid			✔	98%
Valdecoxib			++++ COX-2, IC50: 5 nM	99+%
Ibuprofen		+ COX-1, IC50: 13 μM	+ COX-2, IC50: 370 μM	98%
Indomethacin		++ COX1, IC50: 0.28 μM	+ COX-2, IC50: 14 μM	97%
Lornoxicam		++++ COX-1, IC50: 5 nM	++++ COX-2, IC50: 8 nM	98%
Meclofenamic acid sodium		++++ COX-1, IC50: 40 nM	+++ COX-2, IC50: 50 nM	99%
Asaraldehyde			✔	98%
Naproxen		+ COX-1, IC50: 8.7 μM	+ COX-2, IC50: 5.2 μM	98%
Diclofenac Sodium Salt		+++ COX-1, IC50: 60 nM	+++ COX-2, IC50: 200 nM	98%
NS-398			++ COX-2, IC50: 3.8 μM	95%
Amfenac Sodium Hydrate		++ COX-1, IC50: 250 nM	+++ COX-2, IC50: 150 nM	98%+
Nimesulide			+ COX-2, IC50: 26 μM	98%
Lumiracoxib		++ COX-1, Ki: 3 μM	+++ COX-2, Ki: 60 nM	98%
Rutaecarpine			✔	95%
Celecoxib			++++ COX-2, IC50: 40 nM	98%
Carprofen			++++ canine COX2, IC50: 30 nM	98%
Ketorolac		++ COX-1 (human), IC50: 1.23 μM	++ COX-2 (human), IC50: 3.50 μM	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Chebulagic acid/诃子鞣酸生物活性

描述

Chebulagic acid is a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis.

Chebulagic acid/诃子鞣酸细胞实验

Cell Line MKN1 cells GES-1 cells human rhabdomyosarcoma (RD) cells Vero-E6 cells NUGC3 cells BEAS-2B cells HEp-2 cells A549 cells Madin-Darby canine kidney (MDCK) cells HEp-2 (human epithelial cells derived from a larynx carcinoma) CHO-SLAM (Chinese hamster ovary cells expressing human SLAM) Vero (African green monkey kidney cells) Huh-7.5 (human hepatocarcinoma Huh-7 cell derivative) HEL (human embryonic lung fibroblast) vascular smooth muscle cells (VSMCs) human rhabdomyosarcoma (RD) cells	Concentration	Treated Time	Description	References
MKN1 cells	0, 3, 6, 12 μM	48 h	Inhibited cell proliferation, migration, and induced apoptosis	Front Pharmacol. 2023 Mar 1;14:1143427
GES-1 cells	0–128 μM	48 h	Assessed cytotoxicity	Front Pharmacol. 2023 Mar 1;14:1143427
human rhabdomyosarcoma (RD) cells	12.5 μg/mL (IC50)	2 h post-infection	To evaluate the inhibitory effect of Chebulagic acid on EV71 infection, results showed it significantly reduced viral RNA copies and inhibited cytopathic effects.	Int J Mol Sci. 2013 May 3;14(5):9618-27
Vero-E6 cells	9.76 ±0.42 μM (EC50)	48 h	To evaluate the inhibitory effect of CHLA on SARS-CoV-2 replication. Results showed that CHLA dose-dependently inhibited viral plaque formation with an EC50 of 9.76 ±0.42 μM.	Antiviral Res. 2021 Jun;190:105075
NUGC3 cells	0, 5, 10, 20 μM	48 h	Inhibited cell proliferation, migration, and induced apoptosis	Front Pharmacol. 2023 Mar 1;14:1143427
BEAS-2B cells	5 µM	24 h	To evaluate the inhibitory effect of CHLA on RSV replication, results showed that CHLA significantly inhibited RSV replication.	J Virol. 2024 Dec 17;98(12):e0153624
HEp-2 cells	5 µM	24 h	To evaluate the inhibitory effect of CHLA on RSV replication, results showed that CHLA significantly inhibited RSV replication.	J Virol. 2024 Dec 17;98(12):e0153624
A549 cells	0.07864 µM (IC50)	24 h	To evaluate the inhibitory effect of CHLA on RSV replication, results showed that CHLA significantly inhibited RSV replication.	J Virol. 2024 Dec 17;98(12):e0153624
Madin-Darby canine kidney (MDCK) cells	1.36 ± 0.36 μM	24 h	Evaluate the inhibitory effect of CHLA on influenza A virus replication, results showed CHLA effectively inhibited viral replication	Front Microbiol. 2020 Feb 28;11:182
HEp-2 (human epithelial cells derived from a larynx carcinoma)	1 μM	1.5 h	To evaluate the antiviral activity of CHLA against RSV infection, showing an EC50 of 0.38 ± 0.05 μM.	BMC Microbiol. 2013 Aug 7;13:187
CHO-SLAM (Chinese hamster ovary cells expressing human SLAM)	90 μM	1.5 h	To evaluate the antiviral activity of CHLA against MV infection, showing an EC50 of 34.42 ± 4.35 μM.	BMC Microbiol. 2013 Aug 7;13:187
Vero (African green monkey kidney cells)	25 μM	1.5 h	To evaluate the antiviral activity of CHLA against DENV-2 infection, showing an EC50 of 13.11 ± 0.72 μM.	BMC Microbiol. 2013 Aug 7;13:187
Huh-7.5 (human hepatocarcinoma Huh-7 cell derivative)	50 μM	3 h	To evaluate the antiviral activity of CHLA against HCV infection, showing an EC50 of 12.16 ± 2.56 μM.	BMC Microbiol. 2013 Aug 7;13:187
HEL (human embryonic lung fibroblast)	60 μM	3 days	To evaluate the antiviral activity of CHLA against HCMV infection, showing an EC50 of 25.50 ± 1.51 μM.	BMC Microbiol. 2013 Aug 7;13:187
vascular smooth muscle cells (VSMCs)	5 µM	24 h	Chebulagic acid reduces vascular smooth muscle cell calcification by inhibiting nesfatin-1 activity.	Cell Commun Signal. 2024 Oct 11;22(1):488
human rhabdomyosarcoma (RD) cells	20 µM	1 h	Significantly reduced CVA16 infectivity, inhibited viral binding	Emerg Microbes Infect. 2018 Sep 26;7(1):162

Cell Line

Concentration

Treated Time

Description

References

MKN1 cells

0, 3, 6, 12 μM

48 h

Inhibited cell proliferation, migration, and induced apoptosis

Front Pharmacol. 2023 Mar 1;14:1143427

GES-1 cells

0–128 μM

48 h

Assessed cytotoxicity

Front Pharmacol. 2023 Mar 1;14:1143427

human rhabdomyosarcoma (RD) cells

12.5 μg/mL (IC50)

2 h post-infection

To evaluate the inhibitory effect of Chebulagic acid on EV71 infection, results showed it significantly reduced viral RNA copies and inhibited cytopathic effects.

Int J Mol Sci. 2013 May 3;14(5):9618-27

Vero-E6 cells

9.76 ±0.42 μM (EC50)

48 h

To evaluate the inhibitory effect of CHLA on SARS-CoV-2 replication. Results showed that CHLA dose-dependently inhibited viral plaque formation with an EC50 of 9.76 ±0.42 μM.

Antiviral Res. 2021 Jun;190:105075

NUGC3 cells

0, 5, 10, 20 μM

48 h

Inhibited cell proliferation, migration, and induced apoptosis

Front Pharmacol. 2023 Mar 1;14:1143427

BEAS-2B cells

5 µM

24 h

To evaluate the inhibitory effect of CHLA on RSV replication, results showed that CHLA significantly inhibited RSV replication.

J Virol. 2024 Dec 17;98(12):e0153624

HEp-2 cells

5 µM

24 h

To evaluate the inhibitory effect of CHLA on RSV replication, results showed that CHLA significantly inhibited RSV replication.

J Virol. 2024 Dec 17;98(12):e0153624

A549 cells

0.07864 µM (IC50)

24 h

To evaluate the inhibitory effect of CHLA on RSV replication, results showed that CHLA significantly inhibited RSV replication.

J Virol. 2024 Dec 17;98(12):e0153624

Madin-Darby canine kidney (MDCK) cells

1.36 ± 0.36 μM

24 h

Evaluate the inhibitory effect of CHLA on influenza A virus replication, results showed CHLA effectively inhibited viral replication

Front Microbiol. 2020 Feb 28;11:182

HEp-2 (human epithelial cells derived from a larynx carcinoma)

1 μM

1.5 h

To evaluate the antiviral activity of CHLA against RSV infection, showing an EC50 of 0.38 ± 0.05 μM.